Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GMDTC - Jianersheng (Zhuhai) Pharmaceutical Technology

Next Previous
Drug Profile

GMDTC - Jianersheng (Zhuhai) Pharmaceutical Technology

Latest Information Update: 15 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jianersheng (Zhuhai) Pharmaceutical Technology
  • Class Acyclic hydrocarbons; Amines; Antidotes; Radioprotectives; Small molecules; Sodium compounds
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Heavy metal poisoning

Most Recent Events

  • 04 Jan 2024 Jianersheng (Zhuhai) Pharmaceutical Technology plans a phase Ib trial for Heavy metal poisoning (In adults, In the elderly) in China (IV, Infusion) (NCT06199349)
  • 23 Jun 2023 Jianersheng (Zhuhai) Pharmaceutical Technology has patent pending for GMTDC in China
  • 09 Jun 2023 Adverse event and pharmacodynamics data from a preclinical trial in Heavy metal poisoning released byJianersheng (Zhuhai) Pharmaceutical Technology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top